Kymera soars on positive Phase Ib Clinical trial of KT-621

Shares of US clinical-stage biotech Kymera Therapeutic (Nasdaq: KYMR) leapt almost 33% to $88.48 pre-market, as it announced compelling early results for its first-in-class oral STAT 6 degrade KT-621.

The BroADen Phase Ib atopic dermatitis (AD) study showed robust STAT6 degradation, strong biomarker reductions and competitive EASI reductions in-line to slightly better than Sanofi’s (Euronext: SAN) Dupixent (dupilumab) at a 4-week timepoint.

“The BroADen study results exceeded our highest expectations and provide a powerful additional validation of our industry-leading STAT6 degrader program,” said Nello Mainolfi, founder, president and chief executive of Kymera Therapeutics. “KT-621 demonstrated its potential to deliver a first-in-class once-a-day oral treatment for Type 2 inflammatory diseases across every measure we evaluated, including STAT6 degradation, biomarker modulation, clinical activity, impact on other comorbid Type 2 diseases and safety. The results were in line with, or in some cases numerically exceeded, published data for dupilumab at week 4 and we believe further reinforce Kymera’s pioneering expertise in developing transformative oral small molecules with the potential for the activity and safety of injectable biologics,” he added.